Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease

• Published in: Neuroscience letters 1999-01, Vol.259 (1), p.33-36
• Main Authors: Scacchi, R, Gambina, G, Ruggeri, M, Martini, M.C, Ferrari, G, Silvestri, M, Schiavon, R, Corbo, R.M
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Alpha-1 antichymotrypsin; Alzheimer Disease - blood; Alzheimer Disease - genetics; Alzheimer's disease; Apolipoprotein C1; Apolipoprotein C2; Apolipoprotein E; Apolipoproteins E - blood; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; DNA polymorphisms; Female; Genetic Markers; Humans; Male; Medical sciences; Neurology; Presenilin-1
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/S0304-3940(98)00889-1

Besides apolipoprotein E (APOE) polymorphism, whose association with Alzheimer's disease (AD) has been confirmed in most of the numerous population samples studied, other markers have been investigated. In most cases the association firstly described was not confirmed in subsequent works. Since it is important to examine these associations in as many populations as possible, we investigated APOE, APOC1, APOC2, α-1 antichymotrypsin (ACT) and presenilin-1 (PS-1) polymorphisms in a series of elderly patients with late-onset sporadic AD from Northern Italy and in a sex and age-matched control group. We could not confirm the significantly higher frequency of the ACT*A allele among carriers of APOE e*4 allele described elsewhere, although a similar trend was observed. The APOC2 and the PS-1 distributions were similar between patients and controls. However, we observed a significant difference in the genotype and allele frequencies of APOE and APOC1: patients had higher e*4 and C1*2 allele frequencies. This finding confirms the important role for APOE in AD occurrence. In addition, APOC1 seems to be an interesting marker because, though in strict linkage disequilibrium with APOE, it seems to play an independent role in AD risk. In contrast to previously reported data, plasma apoE concentrations were similar in patients and in controls. An interaction between APOE and APOC1 polymorphisms and apoE levels was observed in patients: subjects carrying the APOE E3/E2 or the APOC1 2-2 genotype have higher apoE concentrations than those who do not.